tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Toxocariasis D014120 3 associated lipids
Translocation, Genetic D014178 20 associated lipids
Tremor D014202 15 associated lipids
Trichomonas Infections D014245 3 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Trypanosomiasis D014352 5 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ulcer D014456 16 associated lipids
Uremia D014511 33 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis D014605 14 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Vascular Diseases D014652 16 associated lipids
Vasculitis D014657 14 associated lipids
Venous Insufficiency D014689 2 associated lipids
Viremia D014766 4 associated lipids
Vision Disorders D014786 10 associated lipids
Vitiligo D014820 2 associated lipids
Vomiting D014839 21 associated lipids
West Nile Fever D014901 1 associated lipids
Wounds, Stab D014951 3 associated lipids
Dementia, Vascular D015140 7 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Carcinoma, Merkel Cell D015266 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Discitis D015299 2 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Scleritis D015423 3 associated lipids
Reperfusion Injury D015427 65 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Histiocytosis D015614 2 associated lipids
HIV Infections D015658 20 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Granuloma Annulare D016460 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Fungemia D016469 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Foot Ulcer D016523 4 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Critical Illness D016638 13 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Liver Failure D017093 5 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Polymyositis D017285 1 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Hyperpigmentation D017495 11 associated lipids
Hypopigmentation D017496 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Porokeratosis D017499 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Kobayashi M et al. FK 506 assay past and present--characteristics of FK 506 ELISA. 1991 Transplant. Proc. pmid:1721258
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
McCauley J et al. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. 1991 Transplant. Proc. pmid:1721290
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Takaori K et al. Effects of FK 506 on in vivo immunity in comparison to cyclosporine. 1991 Transplant. Proc. pmid:1721322
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Keicho N et al. Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. 1991 Cell. Immunol. pmid:1703047
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
White DJ FK506: the promise and the paradox. 1991 Clin. Exp. Immunol. pmid:1703053
McCauley J et al. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. 1991 Transplant. Proc. pmid:1721387
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Masaoka T et al. Phase II study of FK 506 for allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721417
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Lim SM and White DJ The pharmacology of immunosuppression. 1991 Ann. Acad. Med. Singap. pmid:1709344
Rosen MK et al. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and rapamycin binding protein. 1991 Biochemistry pmid:1709363
Sakr MF et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. 1991 Hepatology pmid:1709412
Davies CB et al. Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. 1991 Transplant. Proc. pmid:1721448
Abu-Elmagd K et al. FK 506: a new therapeutic agent for severe recalcitrant psoriasis. 1991 Transplant. Proc. pmid:1721449
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Lodish HF and Kong N Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum. 1991 J. Biol. Chem. pmid:1714445
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Jiang H et al. Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. 1991 Eur Surg Res pmid:1723683
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Marquis-Omer D et al. Stabilization of the FK506 binding protein by ligand binding. 1991 Biochem. Biophys. Res. Commun. pmid:1716886
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Bishop DK and Li W Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. 1992 J. Immunol. pmid:1371128
Hatfield SM and Roehm NW Cyclosporine and FK506 inhibition of murine mast cell cytokine production. 1992 J. Pharmacol. Exp. Ther. pmid:1371158
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Matsukawa W et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. 1992 J. Lab. Clin. Med. pmid:1371298
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Liu J et al. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. 1992 Biochemistry pmid:1373650
Adachi A et al. Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets. 1992 Intern. Med. pmid:1373661
Fruman DA et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1373887
Lake JR et al. Maintenance immunosuppression after liver transplantation. 1992 Semin. Liver Dis. pmid:1373916
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Höllsberg P et al. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. 1992 J. Immunol. pmid:1374452
Schreiber SL and Crabtree GR The mechanism of action of cyclosporin A and FK506. 1992 Immunol. Today pmid:1374612
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Ricordi C et al. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. 1992 Transplant. Proc. pmid:1376512
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Barry JM Immunosuppressive drugs in renal transplantation. A review of the regimens. 1992 Drugs pmid:1281071
Stiff DD et al. Metabolism of FK 506 in differentially induced rat liver microsomes. 1992 Res. Commun. Chem. Pathol. Pharmacol. pmid:1281332
Foor F et al. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. 1992 Nature pmid:1281518
Goldfeld AE et al. Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1281550
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Takai K et al. Effects of FK506 on rat thymic epithelial cells; immunohistochemical study. 1992 Thymus pmid:1378235
Dutz JP et al. Effects of cognate peptides on cytolytic and proliferative activities of cloned cytotoxic T lymphocytes. 1992 Int. Immunol. pmid:1378297
Kenmochi T et al. [The effect of FK506 on segmental pancreas allograft in mongrel dogs]. 1992 Nihon Geka Gakkai Zasshi pmid:1378526
Mouzaki A et al. Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes. 1992 Cytokine pmid:1378764
Ramamoorthy S et al. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. 1992 Pediatr. Res. pmid:1378960
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Fischer G et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. 1992 Mol. Microbiol. pmid:1379319
Rondeau E [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin]. 1992 Nephrologie pmid:1379348
Schreiber SL Immunophilin-sensitive protein phosphatase action in cell signaling pathways. 1992 Cell pmid:1379518
Nielsen JB et al. Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380159
Calvo V et al. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380162
Price DJ et al. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. 1992 Science pmid:1380182
Granelli-Piperno A SRC-related proto-oncogenes and transcription factors in primary human T cells: modulation by cyclosporin A and FK506. 1992 J. Autoimmun. pmid:1380242
Reem GH Molecular mode of action of cyclosporin and FK506 in human thymocytes. 1992 J. Autoimmun. pmid:1380243
Bach JF Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. 1992 J. Autoimmun. pmid:1380245
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Walpoth B et al. Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. 1992 Eur Surg Res pmid:1380460
Petros AM et al. Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. 1992 FEBS Lett. pmid:1380470
Van Thiel DH et al. FK 506 reduces the injury experienced following renal ischemia and reperfusion. 1992 Ren Fail pmid:1380720
Hendey B et al. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. 1992 Science pmid:1384129
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Griffiths RJ et al. Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. 1992 Agents Actions pmid:1384284
Todo S et al. Intestinal transplantation in composite visceral grafts or alone. 1992 Ann. Surg. pmid:1384443